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ABSTRACT 
Objective: To develop an accurate, precise and linear Reverse Phase High Performance Liquid Chromatographic (RP-HPLC) method for 
simultaneous quantitative estimation of Diloxanide furoate and Ornidazole in tablets and validate as per ICH guidelines.  
Methods: The optimized method uses a reverse phase column, Waters Symmetry C18 (250 X 4.6 mm; 5μ), a mobile phase of potassium dihydrogen 
ortho phosphate buffer (20 mM, pH2.3): acetonitrile in the proportion of 40:60 v/v, flow rate of 1.0 ml/min and a detection wavelength of 230 nm 
using a UV detector.  
Results: The developed method resulted in Diloxanide furoate eluting at 5.85 min and Ornidazole at 2.85 min. Diloxanide furoate exhibited linearity 
in the range 22.5-67.5μg/ml, while Ornidazole exhibited linearity in the range 15-45μg/ml. The precision is exemplified by relative standard 
deviations of 1.58% for Diloxanide furoate and 1.53% for Ornidazole. Percentage Mean recoveries were found to be in the range of 95-105 by 
percentage method during accuracy studies.  
Conclusion: A rapid, simple, accurate, precise and linear RP-HPLC method was developed for simultaneous quantitative estimation of Diloxanide 
furoate and Ornidazole in tablets and validated as per ICH guidelines. Hence it can be used for the routine analysis of Diloxanide furoate and 
Ornidazole in tablets in various pharmaceutical industries.  
Keywords: RP-HPLC, Diloxanide furoate, Ornidazole, Method development, Validation. 
 
Ornidazole (fig. 1) chemically is 1-(3-chloro-2-hydroxypropyl)-2-










and a molecular weight of 219.625 g/mol. Ornidazole is a derivative 
of 5-nitro imidazole used as an anti-infective agent [1]. Ornidazole is 
converted into an active form by reduction of its nitro group to 
amine that binds to microbial DNA and prevents nucleic acid 
formation, belonging to the class of bacteriostatic [2]. Ornidazole is 
used for the treatment of bacterial vaginosis, trichomoniasis, 
genitourinary infections in women and men, amoebiasis, giardiasis. It 
is also used in infections against anaerobic bacteria and in the 
treatment of prophylaxis during surgical interventions, particularly 
those involving the colon, and in gynaecological operations [2]. 
Ornidazole has been successfully employed in combination with other 
drugs for peptic ulcers, few types of gastritis, stomach cancers, 
rheumatoid arthritis [3] and in the prophylaxis of Crohn’s disease [4]. 
 
Fig. 1: Structure of ornidazole 
 
Diloxanide furoate (fig. 2) chemically is 4-(N-methyl-2,2-
dichloroacetamido) phenyl-2-furoate having the molecular formula 
as C14H11Cl2NO4
 
 and the molecular weight as 328.147 g/mol [5]. It 
is an effective drug for the treatment of asymptotic persons who are 
passing cysts of Entameba histolytica [6]. It acts principally in the 
bowel lumen and is used in the treatment of the intestinal 
amoebiasis. Diloxanide furoate has been used in the treatment of the 
asymptotic carriers of Entameba histolytica [6] and is excellent 







Fig. 2: Structure of Diloxanide furoate 
 
A detailed literature survey reveals that there exists literature on 
chromatographic methods for Ornidazole alone and in combination 
with other drugs [9-16] and similarly Diloxanide furoate in 
combination with other drugs [17-22] in various matrices. Only one 
literature on RP-HPLC assay method for the simultaneous 
quantitative estimation of Diloxanide furoate and Ornidazole in 
pharmaceutical dosage forms using mixed phosphate buffer at pH 
6.0 is reported, while there is one more research work from our 
analysis lab is accepted using triethyl ammonium phosphate buffer 
(pH 2.3) [23,24]. As there is no literature reported using only 
potassium diydrogen orthophosphate buffer at acidic pH, as aqueous 
media along with acetonitrile as mobile phase, the objective of our 
study to understand the feasibility as a new and a rapid RP-HPLC 
validated method for the simultaneous quantitative estimation of 
Diloxanide furoate and Ornidazole in tablets using potassium 
diydrogen orthophosphate buffer (pH 2.3) as per ICH guidelines. 
MATERIALS AND METHODS 
Chemicals and reagents 
Analytically pure sample of Diloxanide furoate and Ornidazole with 
purities greater than 95% were obtained as gift samples from 
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Chandra Labs, Hyderabad, India and tablet formulation [Amicline 
plus] was procured from Medplus pharmacy, Hyderabad, India with 
labelled amount 375 mg and 250 mg of Diloxanide furoate and 
Ornidazole respectively. Acetonitrile (HPLC grade) was obtained 
from Sigma aldrich (Hyderabad, India), water (HPLC grade), 
Potassium dihydrogen orthophosphate (AR grade), ortho 
phosphoric acid (AR Grade) were obtained from SD Fine chemicals 
(Hyderabad, India), 0.22 and 0.45μm Nylon membrane filters were 
obtained from Spincotech Private Limited, Hyderabad, India.  
Instrument 
HPLC analysis was performed on Shimadzu LC-20AD Prominence 
Liquid Chromatography comprising a LC-20AD pump, Shimadzu 
SPD-20A Prominence UV-VISIBLE detector and a reverse phase C18 
column, Waters Symmetry (250X4.6 mm; 5μ). A manually operating 
Rheodyne injector with 20μL sample loop was equipped with the 
HPLC system. The HPLC system was equipped with “SPINCHROM” 
software. A double beam UV-visible spectrophotometer (Shimadzu, 
model UV-1800) having two matched quartz cells with 1 cm light 
path and loaded with UV probe software (version 2.41) was used for 
recording of spectra and measuring absorbance. An electronic 
analytical weighing balance (0.1 mg sensitivity, Shimadzu AY 220), 
digital pH meter (DELUX model 101), a sonicator (sonica, model 
2200 MH).  
Method 
Selection of wavelength 
Suitable wavelength for the HPLC analysis was determined by 
recording UV spectrums in the range of 200-400 nm for individual 
drug solutions of Ornidazole and Diloxanide furoate. Suitable 
wavelength selected for simultaneous estimation is 230 nm as both 
the drugs were more sensitive at 230 nm (fig. 3-4).  
 
 
Fig. 3: UV spectrum of standard Diloxanide furoate 
 
Chromatographic conditions 
The developed method uses a reverse phase C18 column, Waters 
Symmetry C18 (250 X 4.6 mm; 5μ), mobile phase of potassium 
dihydrogen orthophosphate buffer (pH 2.3): acetonitrile in the 
proportion of 40:60 v/v. The mobile phase was set at a flow rate of 
1.0 ml/min and the volume injected was 20μl for every injection. 
The detection wavelength was set at 230 nm.  
Buffer preparation 
The buffer solution was prepared by weighing 2.72g of potassium 
dihydrogen orthophosphate (KH2PO4
Mobile phase preparation 
) and transferring to 1000 ml 
of HPLC grade water to get 20 mM buffer strength, which was 
adjusted to pH 2.3 using 30% v/v ortho phosphoric acid. Later the 
buffer was filtered through 0.45 μm nylon membrane filter. 
The mobile phase was prepared by mixing buffer and acetonitrile in 
the ratio of 40:60 v/v and later it was sonicated for 10 min for the 
removal of air bubbles. 
 
Fig. 4: UV spectrum of standard Ornidazole 
 
Diluent  
Diluent used is the mobile phase itself. 
Preparation of standard solution  
10 mg of Ornidazole and 15 mg of Diloxanide furoate were weighed 
accurately in 100 ml of volumetric flask and dissolved, in 80 ml of 
mobile phase and volume was made up with mobile phase. From 
stock solution 30µg/ml of Ornidazole and 45µg/ml of Diloxanide 
furoate were prepared further by pipetting out 3 ml and making up 
the solution to 10 ml with mobile phase. This is treated as working 
standards solution, 100% target concentration. 
Preparation of sample solution  
Ten tablets were weighed and taken into a mortar, crushed and then 
uniformly mixed. Test stock solutions of Ornidazole (1000μg/ml) 
and Diloxanide furoate (1500μg/ml) were prepared by transferring 
weight equivalent to 100 mg of Ornidazole and 150 mg of Diloxanide 
furoate to 80 ml of mobile phase which is sonicated for 10 min and 
later made up to 100 ml with mobile phase. This solution was 
filtered using 0.22micron syringe filter. 0.3 ml of the above stock 
solution was pipetted out and made up to 10 ml to get working 
sample solution equivalent to a concentration of 30µg/ml for 
Ornidazole and 45µg/ml for Diloxanide furoate, concentrations 
equal to 100% target concentration. 
RESULTS AND DISCUSSION 
Method development 
A Reverse phase HPLC method was developed keeping in mind the 
system suitability parameters i.e. resolution factor (Rs) between 
peaks, Peak Asymmetry (A), number of theoretical plates (N), 
runtime and the cost effectiveness. The optimized method developed 
resulted in the elution of Ornidazole at 2.85 min and Diloxanide 
furoate at 5.85 min. Fig. 5-6 represents chromatograms of standards 
solution mixture and sample respectively. The total run time is 8 
min. System suitability tests are an integral part of method 
development and are used to ensure adequate performance of the 
chromatographic system. Retention time (RT), number of theoretical 
plates (N), peak resolution (Rs) and Peak Asymmetry (A) were 
evaluated for standards at working concentration. The results given 
in table 1 were within acceptable limits.  
In order to test the applicability of the developed method to a 
commercial formulation, ‘Amicline plus’ tablets was 
chromatographed at working concentration and it is shown in fig. 6. 
The sample peaks were identified by comparing the relative 
retention times with the standard solutions (fig. 5-8). System 
suitability parameters were within the acceptance limits, ideal for 
the chromatographed sample. Integration of separated peak area 
Ashok et al. 
Int J Pharm Pharm Sci, Vol 7, Issue 10, 342-347 
 
344 
was done and each drug concentration was determined by using the 
peak area concentration relationship obtained in the standardization 
step. The protocol affords reproducible quantification of the two 
drugs with error less than 10%, which is the standard level in any 
pharmaceutical quality control. 
 
 
Fig. 5: Typical chromatogram of mixture of standard solutions 
 
 
Fig. 6: Typical chromatogram of sample solution 
 
Method validation 
Validation of the analytical method is the process that establishes by 
laboratory studies in which the performance characteristics of the 
method meet the requirements for the intended analytical application. 
HPLC method developed was validated according to International 
Conference on Harmonization (ICH) guidelines [25] for validation of 
analytical procedures. The method was validated for the parameters 
like linearity, accuracy, system precision, intra-day precision, 
Ruggedness, limit of detection (LOD) and limit of quantitiation (LOQ). 
Specificity 
Peaks obtained in the standards solution and sample solution at 
working concentrations are only because of the drugs as blank has 
no peak at the retention time of Ornidazole and Diloxanide furoate 
standards. Accordingly it can be concluded that, the method 
developed is said to be specific. 
Precision 
System precision 
Six replicate injections of the mixture of standards solution at 
working concentration showed % RSD (Relative Standard Deviation) 
less than 2 concerning peak area for both the drugs, which indicates 
the acceptable reproducibility and thereby the precision of the 
system. System precision results are tabulated in tables 2-3. 
Method precision 
Method precision was determined by performing assay of sample 
under the test of repeatability (Intraday precision) at working 
concentrations.  
Repeatability (Intraday precision) 
Six consecutive injections of the sample from the same 
homogeneous mixture at working concentration showed % RSD less 
than 2 concerning % assay for both the drugs which indicate that the 
method developed is method precise by the test of repeatability and 
hence can be understood that the method gives consistently 
reproducible results (tables 4, 5). 
Table 1: System suitability studies results 
Parameters Acceptance Limits Ornidazole Diloxanide furoate 
Retention time (min) - 2.85 5.85 
Resolution factor (Rs) Not less Than 2 -  11.8 
Number Of Theoretical plates (N)  Not less Than 2000 4312  7117 
Peak Asymmetry   Not More Than 2 1.82  1.83 
 
Table 2: System precision results of ornidazole 
n RT Peak Area 
1 2.86 742.08 
2 2.86 735.18 
3 2.85 724.05 
4 2.85 745.73 
5 2.85 745.07 
Average 2.85 738.426 
SD 0.001 9.056 
%RSD 0.035 1.22 
 
Table 3: System precision results of Diloxanide furoate 
n RT Peak Area 
1 5.86 2218.673 
2 5.86 2211.368 
3 5.85 2211.358 
4 5.84 2216.719 
5 5.84 2200.011 
Average 5.85 2211.6258 
SD 0.007 7.256 
%RSD 0.125 0.32 
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Table 4: Intraday precision results for Ornidazole 
n RT Peak area % Assay 
1 2.86 754.466 100.6 
2 2.86 737.589 98.88 
3 2.85 747.825 100.26 
4 2.85 719.373 96.93 
5 2.85 738.269 98.09 
Average 2.85  98.952 
SD 0.001  1.52 
% RSD 0.035  1.53 
 
Table 5: Intraday precision results for Diloxanide furoate 
n RT Peak area % Assay 
1 5.86 2239.353 100.24 
2 5.86 2291.377 102.56 
3 5.85 2299.476 102.93 
4 5.84 2240.451 100.29 
5 5.84 2205.504 99.24 
Average 5.85 - 101.052 
SD 0.007 - 1.6 
%RSD 0.125 - 1.58 
 
Linearity 
Standard solutions of Diloxanide furoate and Ornidazole at different 
concentrations were prepared. Calibration curves (fig. 7-8) were 
constructed by plotting the concentration level versus 
corresponding peak area for both the drugs. The results show an 
excellent correlation between peak areas and concentration within 
the concentration range of 15-45µg/ml for Ornidazole and 22.5-
67.5µg/ml for Diloxanide furoate (Tables 6-7). The correlation 
coefficients were greater than 0.995 for both the drugs, which meet 
the method validation acceptance criteria and hence the method is 
said to be linear for both the drugs. 
 
Table 6: Calibration data for Diloxanide furoate 
% Level Concentration  (µg/ml)  Peak area 
50 22.5 1071.768 
75 33.75 1724.797 
100 45 2206.195 
125 56.25 2782.528 






  0.9959 
 
Table 7: Calibration data for Ornidazole 
% Level Concentration  (µg/ml)  Peak area 
50 15 330.944 
75 22.5 541.632 
100 30 698.95 
125 37.5 866.609 
150 45  1009.345 






Accuracy was determined by means of recovery experiments, by the 
determination of % mean recovery of both the drugs at three 
different levels (50-150%). At each level, three determinations were 
performed. Percent mean recovery is calculated as shown in tables 
8-9. The accepted limits of mean recovery are 95%-105% by 
percentage method and all observed data were within the required 
range, which indicates good recovery values and hence the accuracy 
of the method developed. 
 
 
Fig.7: Linearity graph of Diloxanide furoate 
 
 
Fig. 8: Linearity graph of Ornidazole 
 
Ruggedness 
Ruggedness was evaluated by performing assay of the formulations 
by different analyst by injecting six consecutive injections of the 
sample at working concentration from the same homogeneous 
mixture of tablets. This study showed % RSD less than 2 concerning 
% assay for both the drugs which indicate that the method 
developed is rugged and hence can be understood that the method 
gives reproducible results irrespective of analyst (table 10). 
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Table 8: Recovery studies for Diloxanide furoate 
% Level  % Recovery % Mean recovery  
50 102.23  
50 102.01  102.12 
50 102.12  
100 100.24  
100 102.56  101.91 
100 102.93  
150 101.28  
150 101.05   101.54 
150 102.31  
 
Table 9: Recovery studies for Ornidazole 
% Level  % Recovery % Mean recovery 
50 102.03  
50 100.56 101.05 
50 100.56  
100 100.6  
100 98.88 99.91 
100 100.26  
150 102.96  
150 102.05 102.65 
150 102.96  
 
Table 10: Ruggedness results of Diloxanide furoate and Ornidazole 
n Diloxanide furoate Ornidazole 
 % Assay % Assay 
1  99.8  103.3 
2  98.7 102.1 
3 100.6 101.9 
4 100.3 101.5 
5 99.9 103.5 
6 100.1 102.3 
Average 99.9 102.4 
S. D. 0.654  0.796 
% RSD 0.654 0.77 
 
CONCLUSION 
A rapid, simple, accurate, precise and linear RP-HPLC method was 
developed for simultaneous quantitative estimation of Diloxanide 
furoate and Ornidazole in tablets and validated as per ICH 
guidelines. Hence it can be used for the routine analysis of 
Diloxanide furoate and Ornidazole in tablets in various 
pharmaceutical industries.  
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